Myriad Launches ctDNA Test, Eyes Broader Oncology Market
Event summary
- Myriad Genetics launched Precise MRD, a tumor-informed circulating tumor DNA (ctDNA) assay, with a limited release to select community oncologists.
- The test uses whole-genome sequencing to detect ctDNA at a sensitivity of one part per million.
- Initial availability is focused on breast cancer patients, with a broader U.S. commercial launch planned for later in 2026.
- The test provides longitudinal monitoring during cancer treatment, aiding in treatment decisions and detecting recurrence.
The big picture
Myriad's Precise MRD launch represents a strategic shift towards higher-margin, personalized diagnostics within the oncology space. The test addresses a growing demand for earlier cancer detection and treatment monitoring, driven by advancements in ctDNA technology and a desire to reduce reliance on traditional imaging. However, the limited initial release and dependence on reimbursement raise questions about the test’s long-term commercial viability and Myriad’s ability to compete in a rapidly evolving market.
What we're watching
- Market Adoption
- The success of Precise MRD hinges on adoption rates among community oncologists, which will be influenced by reimbursement policies and clinical validation data beyond the initial release.
- Competitive Landscape
- While Myriad emphasizes precision, other diagnostics companies are also developing ctDNA assays; the test’s differentiation and pricing will be critical for sustained market share.
- Expansion Scope
- Myriad’s stated plan to expand Precise MRD to other cancer types will determine the overall revenue potential and require significant investment in assay development and clinical trials.
Related topics